Where Arcutis Biotherapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Arcutis Biotherapeutics (NASDAQ:ARQT) in the last quarter. According to 6 analysts offering 12-month price targets in the last 3 months, Arcutis Biotherapeutics has an average price target of $42.17, a decrease from the previous average price target of $65.00.
September 25, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arcutis Biotherapeutics has received bullish ratings from analysts, but the average price target has decreased.
While the bullish ratings from analysts are a positive sign, the decrease in the average price target could indicate a potential decrease in the stock's value in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100